Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Report date: October 18, 2021. The filing reports preliminary liquidity information and topline results from the Phase 3 PHALCON-EE trial of vonoprazan for erosive esophagitis (EE).
Business Context and Reporting Period
- Phathom is developing vonoprazan for the healing and maintenance of healing of EE and relief of heartburn.
- The filing does not provide results of operations for the three or nine months ended September 30, 2021; it provides preliminary cash information as of that date.
- PHALCON-EE evaluated vonoprazan against lansoprazole in a Healing Phase of up to eight weeks and a Maintenance Phase of 24 weeks.
Financial and Liquidity Metrics
| Metric | Reported information |
|---|---|
| Cash and cash equivalents at September 30, 2021 | Approximately $225 million, preliminary and unaudited |
| New debt drawdown | $100 million under the Loan and Security Agreement with Hercules Capital |
| Refinanced debt | Approximately $54 million paid to retire the prior Silicon Valley Bank credit facility |
| Additional borrowing availability | Potential access to an additional $50 million under the Hercules agreement, subject to lender conditions and milestone verification |
| Revenue, net income, operating cash flow, margins and debt balance | The filing text does not provide clear values |
Clinical Results and Material Changes
- Healing Phase: Vonoprazan 20 mg achieved 93% healing by Week 8 versus 85% for lansoprazole 30 mg, meeting non-inferiority and a preplanned exploratory superiority test, both with p<0.0001.
- Among patients with moderate-to-severe EE, Week 2 healing was 70% for vonoprazan versus 53% for lansoprazole, with p=0.0004.
- Vonoprazan did not achieve statistically significant superiority for sustained heartburn resolution by Day 3: 34% versus 32%, p=0.2196.
- Maintenance Phase: Healing was maintained through Week 24 in 81% of patients receiving vonoprazan 20 mg, 79% receiving vonoprazan 10 mg and 72% receiving lansoprazole 15 mg. Both vonoprazan doses met non-inferiority and superiority endpoints.
- For moderate-to-severe EE, maintenance rates were 77% for vonoprazan 20 mg, 75% for vonoprazan 10 mg and 61% for lansoprazole 15 mg.
- Mean 24-hour heartburn-free days were non-inferior to lansoprazole in both study phases.
Safety, Outlook and Risks
- The company stated that the safety profile was consistent with prior studies. The most common Healing Phase adverse event was diarrhea: 2.1% for vonoprazan 20 mg and 2.5% for lansoprazole 30 mg.
- Maintenance Phase serious adverse events occurred in 4.7% of patients receiving vonoprazan 20 mg, 3.4% receiving vonoprazan 10 mg and 2.4% receiving lansoprazole 15 mg.
- Seven COVID-19 serious adverse events occurred across both phases; two patients died. Investigators did not consider these events related to study drug.
- Phathom plans to submit an NDA to the FDA in the first half of 2022, expects an FDA decision in 2023 and anticipates a potential 2023 commercial launch if approved.
- The company plans to present full PHALCON-EE results at a medical meeting and submit them for publication.
- Key risks include changes following additional audit and verification of topline data, FDA disagreement or delays affecting the NDA, conditions limiting access to the additional $50 million, manufacturing and supply-chain dependence, regulatory uncertainty, adverse effects or inadequate efficacy, intellectual-property and licensing matters, and COVID-19-related operational disruption.
Investor Verification Checklist
- Verify final audited third-quarter 2021 financial statements, including cash, operating expenses, net loss, cash burn and total debt.
- Confirm whether the additional $50 million under the Hercules facility was drawn and review applicable covenants, milestones, interest and repayment terms.
- Review the complete PHALCON-EE dataset, including patient disposition, statistical methodology, adverse events and final audited results.
- Track the timing and contents of the NDA submission, FDA acceptance, review milestones and any approval or labeling limitations.
- Assess funding needs and dilution or debt-financing risks through a potential 2023 launch.